Fig. 5.

Patient overall survival (a), death-censored graft survival (b) after living donor kidney transplantation for the three groups (heparin, nonheparin, no IA). During the study period, 13 patients died (235 patients with 1,017 patient years at risk). The mortality did not significantly differ between the three treatment groups (log-rank test p = 0.5479; Wilcoxon test p = 0.4450). Twelve patients had a graft failure (235 patients with 1,016 patient years at risk). Graft failure did not significantly differ between the treatment groups (log-rank test p = 0.938; Wilcoxon test p = 0.667).